AIMS: We report the results of a retrospective study of stereotactic body radiotherapy (SBRT) using a Cyberknife for prostate cancer. METHODS: In all 29 patients were treated with hypofractionated SBRT using a Cyberknife at median 36 Gy in five fractions. All the patients were treated with a radical aim. Prostate-specific antigen (PSA) was evaluated at baseline and after radiotherapy. Acute (≤3 months) and late (>3 months) urinary and rectal toxicities were recorded according to the CTCAE version 4.0. RESULTS: The median duration of follow up was 41 months. PSA values decreased in a time-dependent way. The median PSA nadir was 0.329 ng/mL, achieved after a median of 23 months' follow up. Two patients had a PSA failure according to the definition of nadir + 2 ng/mL. Eight patients (28%) had a benign PSA bounce at median 9 months after radiotherapy. CTCAE Grade 2 and 3 late urinary toxicities were reported in 3 and 3%, respectively. One patient had exacerbated urinary symptoms and received an operation. There were no severe late rectal toxicities. CONCLUSIONS: The preliminary findings of our study suggest SBRT is feasible for prostate cancer treatment. Further studies with more patients and longer follow-up duration are required.
AIMS: We report the results of a retrospective study of stereotactic body radiotherapy (SBRT) using a Cyberknife for prostate cancer. METHODS: In all 29 patients were treated with hypofractionated SBRT using a Cyberknife at median 36 Gy in five fractions. All the patients were treated with a radical aim. Prostate-specific antigen (PSA) was evaluated at baseline and after radiotherapy. Acute (≤3 months) and late (>3 months) urinary and rectal toxicities were recorded according to the CTCAE version 4.0. RESULTS: The median duration of follow up was 41 months. PSA values decreased in a time-dependent way. The median PSA nadir was 0.329 ng/mL, achieved after a median of 23 months' follow up. Two patients had a PSA failure according to the definition of nadir + 2 ng/mL. Eight patients (28%) had a benign PSA bounce at median 9 months after radiotherapy. CTCAE Grade 2 and 3 late urinary toxicities were reported in 3 and 3%, respectively. One patient had exacerbated urinary symptoms and received an operation. There were no severe late rectal toxicities. CONCLUSIONS: The preliminary findings of our study suggest SBRT is feasible for prostate cancer treatment. Further studies with more patients and longer follow-up duration are required.
Authors: Nam P Nguyen; Rick Davis; Satya R Bose; Suresh Dutta; Vincent Vinh-Hung; Alexander Chi; Juan Godinez; Anand Desai; William Woods; Gabor Altdorfer; Mark D'Andrea; Ulf Karlsson; Richard A Vo; Thomas Sroka Journal: Front Oncol Date: 2015-02-02 Impact factor: 6.244
Authors: Ping Jiang; Katja Krockenberger; Reinhard Vonthein; Jane Tereszczuk; Arne Schreiber; Sebastian Liebau; Stefan Huttenlocher; Detlef Imhoff; Panagiotis Balermpas; Christian Keller; Kathrin Dellas; Rene Baumann; Claus Rödel; Guido Hildebrandt; Klaus-Peter Jünemann; Alex S Merseburger; Alan Katz; Andreas Ziegler; Oliver Blanck; Jürgen Dunst Journal: Radiat Oncol Date: 2017-08-18 Impact factor: 3.481
Authors: Andrew W Ju; Hongkun Wang; Eric K Oermann; Benjamin A Sherer; Sunghae Uhm; Viola J Chen; Arjun V Pendharkar; Heather N Hanscom; Joy S Kim; Siyuan Lei; Simeng Suy; John H Lynch; Anatoly Dritschilo; Sean P Collins Journal: Radiat Oncol Date: 2013-01-31 Impact factor: 3.481
Authors: Yong Hyun Park; In Young Choi; Sei Chul Yoon; Hong Seok Jang; Hyong Woo Moon; Sung-Hoo Hong; Sae Woong Kim; Tae-Kon Hwang; Ji Youl Lee Journal: Prostate Int Date: 2015-02-12
Authors: Vladimir Avkshtol; Yanqun Dong; Shelly B Hayes; Mark A Hallman; Robert A Price; Mark L Sobczak; Eric M Horwitz; Nicholas G Zaorsky Journal: Res Rep Urol Date: 2016-08-18